Literature DB >> 12511957

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis.

Laurent O Martinez1, Sébastien Jacquet, Jean-Pierre Esteve, Corinne Rolland, Elena Cabezón, Eric Champagne, Thierry Pineau, Valérie Georgeaud, John E Walker, François Tercé, Xavier Collet, Bertrand Perret, Ronald Barbaras.   

Abstract

The effect of high-density lipoprotein (HDL) in protecting against atherosclerosis is usually attributed to its role in 'reverse cholesterol transport'. In this process, HDL particles mediate the efflux and the transport of cholesterol from peripheral cells to the liver for further metabolism and bile excretion. Thus, cell-surface receptors for HDL on hepatocytes are chief partners in the regulation of cholesterol homeostasis. A high-affinity HDL receptor for apolipoprotein A-I (apoA-I) was previously identified on the surface of hepatocytes. Here we show that this receptor is identical to the beta-chain of ATP synthase, a principal protein complex of the mitochondrial inner membrane. Different experimental approaches confirm this ectopic localization of components of the ATP synthase complex and the presence of ATP hydrolase activity at the hepatocyte cell surface. Receptor stimulation by apoA-I triggers the endocytosis of holo-HDL particles (protein plus lipid) by a mechanism that depends strictly on the generation of ADP. We confirm this effect on endocytosis in perfused rat liver ex vivo by using a specific inhibitor of ATP synthase. Thus, membrane-bound ATP synthase has a previously unsuspected role in modulating the concentrations of extracellular ADP and is regulated by a principal plasma apolipoprotein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511957     DOI: 10.1038/nature01250

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  138 in total

Review 1.  Reverse cholesterol transport: high-density lipoprotein's magnificent mile.

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Using bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an MRL/MpJ x SM/J intercross.

Authors:  Magalie S Leduc; Rachael Hageman Blair; Ricardo A Verdugo; Shirng-Wern Tsaih; Kenneth Walsh; Gary A Churchill; Beverly Paigen
Journal:  J Lipid Res       Date:  2012-04-11       Impact factor: 5.922

4.  Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: implications for antitumor activity.

Authors:  Monika Deshpande; Luigi Notari; Preeti Subramanian; Vicente Notario; S Patricia Becerra
Journal:  Int J Oncol       Date:  2012-04-10       Impact factor: 5.650

Review 5.  Ecto-F₁-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor.

Authors:  Pierre Vantourout; Claudia Radojkovic; Laeticia Lichtenstein; Véronique Pons; Eric Champagne; Laurent O Martinez
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 6.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

7.  Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.

Authors:  Ilian A Radichev; Albert G Remacle; Nor Eddine Sounni; Sergey A Shiryaev; Dmitri V Rozanov; Wenhong Zhu; Natalya V Golubkova; Tatiana I Postnova; Vladislav S Golubkov; Alex Y Strongin
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

8.  High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.

Authors:  Bin Lou; Xue-Ling Liao; Man-Ping Wu; Pei-Fang Cheng; Chun-Yan Yin; Zheng Fei
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 9.  Hepatic high-density lipoprotein receptors: roles in lipoprotein metabolism and potential for therapeutic modulation.

Authors:  Bernardo L Trigatti
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 10.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.